This case involves a scenario between researches in U.S. and abroad, and the differences in research-related regulations between countries that can still compromise a study.
A collaborative research venture involves institutions from the United States and a foreign country. Although the study will be conducted abroad, U.S. researchers’ protocol underwent their institutional IRB review, while there is no such requirement for their foreign colleagues. As the study is underway, a situation threatens the promise of confidentiality for participants and thus the integrity of the research design. These participants are HIV positive patients receiving care, and who are citizens of the foreign country. Although the foreign investigators inform their U.S. counterparts that they are providing the National Health numbers of patients in order for outside laboratories to be paid, these researchers do not exhibit concerned since they are not obliged to follow the same regulations as U.S. researchers. Dr. Alexie Filipovna (co-principal investigator) and Dr. Syd Shingles, the U.S. researchers, discuss what they perceive as a threat to data integrity with a representative of the foreign research team, Dr. Raymond Lagarde.
Taking the role of the co-principal investigator, decide to act on one of the following options: |
